Translate page

iCMLf Expert Opinions

This section provides you with a selection of expert opinions from leaders in the field. 

You will find interviews with CML experts providing their personal perspectives on highlights from scientific meetings and latest scientific advancements as well as keynote presentations from iCMLf prize winners. The topics featured cover a broad range of issues from CML science to clinical practice.   

 

Highlights from the John Goldman Conference on CML 2019:
CML experts give their personal perspectives

Perspectives on the clinical aspects of the meeting from Professor Jorge Cortes
Georgia Cancer Center
Augusta University, Augusta (USA)

  • Treatment-free remission as a new goal for patients with CML
    • Long-term follow-up data from the STIM study
    • Treatment strategies for patients with early and late relapse 
    • Biomarkers to predict a higher probability of relapse
    • Pharmacoeconomics of treatment discontinuation
  • Complex genetics of CML - the work of the Genomics Alliance
  • Clinical trial updates
    • SPIRIT trial
    • BEYOND study
    • Asciminib combinations
  • Fatigue during TKI therapy

 

Perspectives on the scientific aspects of the meeting from Professor Daniela Krause
Georg-Speyer Haus
University of Frankfurt (Germany) 

  • Concept of treatment-free remission
    • Immunological surveillance after treatment discontinuation
    • Analysis of different immune subsets 
    • A mathematical model for prediction of good response
  • Results from the workshop on metabolism 
  • The role of inflammation in CML
  • Aging - mutations that occur with aging
  • Therapy resistance
  • Stem cells and microenvironment
  • Existence of BCR-ABL independent mutations
  • Immunotherapy - resistance to CAR-T cells

 We apologize for the background noise in this video.

Highlights from ASH 2018 Annual Meeting:

At ASH in San Diego, the CML education session was entitled 'With Great Success Comes Great Responsibility'. Professors Jane Apperley, Timothy Hughes and Charles Craddock gave respective presentations on the treatment of CML with TKIs, molecular monitoring to aid clinical decision making and the role of transplantation in managing CML. Below are interviews from the presenters on their perspectives on the session. 

These summaries are brought to you with support from Bristol Myers Squibb.

In addition, we are pleased to be able to offer you a complete scientific summary of the education session on CML. This also contains a summary of relevant abstracts on; TFR failure, resistance and new drug development.

Download the scientific summary report here

Summaries of the ASH CML Education Session


The Argument for Using Imatinib in CML

Professor Jane Apperley
Imperial College London, London, UK

Jane Apperley described the outcome of newly diagnosed patients newly treated with first or second generation TKIs. She discussed balancing the desire to achieve the deep molecular responses that permit trials of TKI discontinuation with the potential adverse effects of earlier use of the more potent TKI's, and provided pragmatic advice regarding treatment decisions.  

Importance of Molecular Monitoring in CML: How Deep, How Often, and How Should it Influence Therapy?

Professor Timothy Hughes
Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

Tim Hughes explored the appropriate time-dependent molecular targets for CML patients on TKI and the reasons why those targets differ, especially when considering treatment discontination. He also discussed the facts that influence the choice of TKI when molecular responses are not optimal and highlighted the critical role of molecular monitoring in managaging treatment-free remission.   

We Do Still Transplant CML, Don't We?

Professor Charles Craddock
Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK

Charles Craddock summarised the results of alloSCT in all phases of CML and discussed factors affecting decision-making now that increased donor availability and reduced intensity conditioning regimes have increased the number of transplant eligible patients. As disease relapse remains a major cause of treatment failure he focused on emerging peri- and post-transplant strategies to improve the outcome.   

Highlights from the John Goldman Conference on CML 2018:
CML experts give their personal perspectives

In Spanish:
Perspectivas sobre los estudios de discontinuación de terapia que se mostraron
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina

  • Resumen de los estudios de discontinuacíon de terapia más importantes, que incluyen
    • ENESTFreedom
    • ENESTStop
    • DASFree
  • Análisis de los estudios actuales sobre biomarcadores y otros factores predictivos que pueden predecir el éxito terapéutico y que pueden mostrar qué mutaciones pueden ser relevantes en pacientes resistentes

Perspectives on the clinical aspects of the meeting from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)

  • Update on new studies including TIGER and SPIRIT II 
  • Long-term outcomes from clinical studies on treatment-discontinuation
  • Various aspects on treatment-free-remission such as predictors of success, biomarkers, gene analysis, use of digital PCR, pregnancy
  • New modalities and tools of monitoring patients 
  • Biology of CML and the role of microenvironment and molecular abnormalities

 

Perspectives on the scientific aspects of the meeting from Professor Daniela Krause
Georg-Speyer Haus
University of Frankfurt (Germany) 

  • Scientific workshops on imaging and genome editing
  • Novel strategies with new pathways complementing existing TKI therapies
  • Skeleton muscle toxicities induced by TKI's
  • Possible relationship between dopamin receptors and leukemic stem cell receptors
  • Debate on eradicating remaining stem cells
  • Innovative new technologies for monitoring

 

Highlights from the John Goldman Conference on CML 2017:
CML experts give their personal perspectives

In Spanish:
Perspectivas sobre nuevas estudios clínicos y cómo se transfieren al mundo real - especialmente en países en vía de desarollo
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina

  • Actualización del estudio CML-IV: Seguridad y eficacia de imatinib durante 10 años
  • Actualización del estudio PACE: Uso de ponatinib en segunda y tercera línea
  • Varios estudios clínicos del discontinuación del tratamiento y qué aspectos deberían considerarse en la aplicación práctica
  • Tratamiento de la población pediátrica y el uso de nuevas tecnologías para el monitoreo molecular

 

Highlights from the John Goldman Conference on CML 2017:
CML experts give their personal perspectives

Perspectives on biology and clinical aspects 
from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)

  • Leukemic stem cells and microenvironment
  • Biomarkers 
  • Conceptual understanding of treatment-free remission 
  • Treatment discontinuation with 2nd generation TKI's
  • Update on the new ELN recommendations
  • Patient-reported outcomes
  • New modalities of monitoring patients
  • Long-term outcomes from various clinical studies

 

Keynote presentations from the recipients of the 2017 iCMLf Prizes

At the 19th Annual John Goldman Conference on CML in Estoril the iCMLf Directors awarded the Foundation’s 2017 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

iCMLf Prize recipients 2017

 

 

  • 2017 Goldman Prize: Professor Timothy Hughes
  • 2017 iCMLf Prize: Professor Jerald Radich
  • 2017 Rowley Prize: Professor Tessa Holyoake 

At Tessa’s request, her keynote was presented by Mhairi Copland, Professor of Translational Haematology at the Paul O’ Gorman Leukemia Research Center at the University of Glasgow.

 

Highlights from EHA 2017:
2 CML experts give their personal perspectives

Perspectives on new CML studies from
Professor Timothy Hughes
South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, Royal Adelaide Hospital, Australia

  • Phase II study on dasatinib in children and adolescents with CML-CP
  • 10-year survival results of the German CML IV Study
  • Year 2 results from the British Destiny Study 
  • Initial results from the Before trial: Bosutinib vs. Imatinib in newly diagnosed CML
  • Update on treatment-free remission studies

 

Perspectives on CML management

from Professor Jerry Radich
Fred Hutchinson Cancer Research Center
Seattle, USA

  • Assessment of existing therapies in CML including new data on bosunitib in front-line therapy
  • Emerging new therapies for CML and how they could come into practice
  • Perspectives on treatment discontinuation
  • Challenges of CML management in the emerging economic regions: access to treatment and testing

Highlights from ASH 2016:
3 CML experts give their personal perspectives

This independent educational resource is supported by a grant from Novartis Oncology

Perspectives on molecular monitoring in CML from 
Associate Professor Susan Branford, PhD
Center for Cancer Biology
SA Pathology, Adelaide, Australia

  • Treatment-free remission studies including an update of the EURO-SKI trial
  • New data on optimal timing for monitoring patients after stopping therapy
  • Additional chromosomal abnormalities and their impact on prognosis
  • Next generation sequencing technologies 

Perspectives from Professor Jorge Cortes, MD

MD Anderson Cancer Center
University of Texas, Houston, USA

  • Different aspects on treatment discontinuation including 2nd treatment discontinuation and QoL assessment
  • Presentation of a new tyrosine kinase inhibitor
  • Generics making it into practice
  • Predictive markers and their impact on patients outcome
  • Considerations for treatment discontinuation in clinical practice including AE management

Perspectives on QoL assessment in CML patients from Dr Fabio Efficace, PhD 

Fondazione GIMEMA, Rome, Italy

Northwestern University, Feinberg School of Medicine, Chicago, USA

  • Importance of QoL assessment in CML
  • Correlation between QoL and adherence to therapy
  • Update on QoL data from the ENEST trials
  • Overview of measuring instruments to assess QoL and the importance of patient-related QoL measures

 

 

Keynote presentations from the recipients of the 2016 iCMLf Prizes

At the 18th Annual John Goldman Conference on CML in Houston the iCMLf Directors awarded the Foundation’s 2016 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

Collage 2016 Keynotes Prizes

 

  • 2016 Rowley Prize: Professor Nora Heisterkamp 
  • 2016 Goldman Prize: Professor Hagop Kantarjian
  • 2016 iCMLf Prize: Associate Professor Susan Branford
 

Highlights from EHA 2016:
3 CML experts give their personal perspectives

This independent educational resource is supported by a grant from Novartis Oncology



Perspectives from Prof. Michele Baccarani
Chairman of CML Working Party of European LeukemiaNet,
Founding member of the iCMLf, Università di Bologa, Italy

  • The unmet needs in CML
  • Pathways to treatment free response
  • Next generation sequencing - the impact on future treatment decision making


Perspectives from Prof. Francois-Xavier Mahon
University de Bordeaux, France

  • Perspectives on treatment discontinuation
  • Proposed critieria for stopping TKI therapy
  • Highlights of EHA